Dr. Scagliotti Discusses Elderly Lung Cancer Therapy

Giorgio V. Scagliotti, MD, PhD
Published: Wednesday, Oct 19, 2011

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses the challenges facing lung cancer treatment in elderly populations.

Scagliotti explains that elderly patients now represent approximately 30% of new non-small cell lung cancer (NSCLC) patients. Despite this fact there hasn't been any major recent advances in the treatment of elderly patients with NSCLC.

The current standard treatment for NSCLC is chemotherapy that is either a targeted therapy or a classic cytotoxic agent. Administering combination therapies becomes difficult for elderly patients because only a minority is fit enough for this type of treatment.

The degree of comorbid conditions is increased in elderly patients due to their physiological state. These conditions are exceptionally common when giving cisplatin, which is the backbone of many combinations therapies.

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses the challenges facing lung cancer treatment in elderly populations.

Scagliotti explains that elderly patients now represent approximately 30% of new non-small cell lung cancer (NSCLC) patients. Despite this fact there hasn't been any major recent advances in the treatment of elderly patients with NSCLC.

The current standard treatment for NSCLC is chemotherapy that is either a targeted therapy or a classic cytotoxic agent. Administering combination therapies becomes difficult for elderly patients because only a minority is fit enough for this type of treatment.

The degree of comorbid conditions is increased in elderly patients due to their physiological state. These conditions are exceptionally common when giving cisplatin, which is the backbone of many combinations therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x